Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced interim results from 32 patients treated to date in a phase I clinical trial of ADCETRIS administered in combination with or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma and other CD30-positive mature T-cell lymphoma patients.
View original post here:
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell Lymphomas